Financials data is unavailable for this security.
View more
Year on year Tasly Pharmaceutical Group Co Ltd had relatively flat revenues (8.64bn to 8.67bn), though the company grew net income from a loss of 264.24m to a gain of 1.07bn. A reduction in the cost of goods sold as a percentage of sales from 36.44% to 33.26% was a component in the net income growth despite flat revenues.
| Gross margin | 65.99% |
|---|---|
| Net profit margin | 11.36% |
| Operating margin | 13.80% |
| Return on assets | 5.65% |
|---|---|
| Return on equity | 8.31% |
| Return on investment | 6.96% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Tasly Pharmaceutical Group Co Ltd fell by 730.54m. However, the company earned 2.58bn from its operations for a Cash Flow Margin of 29.69%. In addition the company used 2.11bn on investing activities and also paid 1.20bn in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 8.39 |
|---|---|
| Tangible book value per share | 6.97 |
More ▼
Balance sheet in CNYView more
| Current ratio | 2.95 |
|---|---|
| Quick ratio | 2.40 |
| Total debt/total equity | 0.2992 |
|---|---|
| Total debt/total capital | 0.2259 |
More ▼
Growth rates in CNY
Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items increased 498.30%. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 2.29% |
|---|---|
| Div growth rate (5 year) | 1.92% |
| Payout ratio (TTM) | 85.89% |
| EPS growth(5 years) | -6.84 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 18.37 |
More ▼
